|

Azacytidine Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Also known as: 5-AZC, 5-aza, 5-azacytidine, AZA-CR, Ladakamycin +2 more

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • National Cancer Institute (NCI)1
  • M.D. Anderson Cancer Center1

Indications

  • Cancer2
  • Non-Small Cell Lung Carcinoma1
  • Hodgkin's Lymphoma1
  • Non-small Cell Lung Cancer (NSCLC)1
  • Carcinoma, Non-Small-Cell Lung1

Bethesda, Maryland1 trial

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center

Phase 1/2

Houston, Texas1 trial

A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma

MD Anderson Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.